Harbor Capital Advisors Inc. Invests $3.68 Million in Glaukos Co. (NYSE:GKOS)

Harbor Capital Advisors Inc. acquired a new stake in Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 24,539 shares of the medical instruments supplier’s stock, valued at approximately $3,679,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in shares of Glaukos in the third quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd raised its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the period. KBC Group NV lifted its position in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares during the last quarter. Brighton Jones LLC bought a new stake in Glaukos during the second quarter valued at about $208,000. Finally, EWA LLC acquired a new stake in shares of Glaukos in the third quarter valued at about $209,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,603 shares of company stock worth $2,605,678 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on GKOS. BTIG Research raised their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stifel Nicolaus raised their price objective on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company. Wells Fargo & Company boosted their price objective on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. increased their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $147.75.

Glaukos Stock Down 0.7 %

NYSE:GKOS opened at $156.96 on Friday. The stock’s fifty day moving average price is $143.78 and its two-hundred day moving average price is $131.82. The company has a market cap of $8.65 billion, a price-to-earnings ratio of -51.97 and a beta of 1.04. Glaukos Co. has a 52-week low of $83.90 and a 52-week high of $161.13. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same period last year, the company earned ($0.50) earnings per share. The company’s revenue was up 23.9% on a year-over-year basis. On average, analysts anticipate that Glaukos Co. will post -1.89 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.